Adenosine receptors in GtoPdb v.2021.2
暂无分享,去创建一个
B. Fredholm | K. Klotz | K. Jacobson | A. IJzerman | C. Müller | B. Frenguelli | G. Stiles | J. Linden | U. Schwabe | R. Hills
[1] Wei Liu,et al. Cryo-EM structure of the human adenosine A2B receptor–Gs signaling complex , 2022, Science advances.
[2] K. Jacobson,et al. Structure-Activity Studies of 1H-Imidazo[4,5-c]quinolin-4-amine Derivatives as A3 Adenosine Receptor Positive Allosteric Modulators. , 2022, Journal of medicinal chemistry.
[3] R. Stevens,et al. GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A2A Adenosine Receptor , 2022, Journal of medicinal chemistry.
[4] K. Jacobson,et al. Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A3 Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary. , 2021, Journal of Medicinal Chemistry.
[5] James D. Clarke,et al. Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity , 2020, Journal for ImmunoTherapy of Cancer.
[6] M. Hung,et al. ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. , 2020, Cancer cell.
[7] Peter Buneman,et al. Why data citation isn't working, and what to do about it , 2020, Database J. Biol. Databases Curation.
[8] Jeroen J. Bax,et al. Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double‐blind, placebo‐controlled trial , 2019, European journal of heart failure.
[9] J. Powers,et al. Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers , 2019, Investigational New Drugs.
[10] K. Varani,et al. Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity. , 2019, Journal of medicinal chemistry.
[11] Andrew P. Vreede,et al. Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome , 2019, Nature Communications.
[12] A. IJzerman,et al. Development of Covalent Ligands for G Protein-Coupled Receptors: A Case for the Human Adenosine A3 Receptor , 2019, Journal of medicinal chemistry.
[13] B. Kalthof,et al. Novel non-xanthine antagonist of the A2B adenosine receptor: From HTS hit to lead structure. , 2019, European journal of medicinal chemistry.
[14] K. Jacobson,et al. Design and in Vivo Characterization of A1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series. , 2019, Journal of medicinal chemistry.
[15] M. Kulka,et al. Adenosine activates G&agr;s proteins and inhibits C3a‐induced activation of human mast cells , 2018, Biochemical pharmacology.
[16] A. Hotson,et al. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models , 2018, Cancer Immunology Research.
[17] W. Baumeister,et al. Structure of the adenosine-bound human adenosine A1 receptor–Gi complex , 2018, Nature.
[18] L. Peletier,et al. A two‐state model for the kinetics of competitive radioligand binding , 2018, British journal of pharmacology.
[19] Christopher G Tate,et al. Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein , 2018, bioRxiv.
[20] K. Garber. Adenosine checkpoint agent blazes a trail, joins immunotherapy roster , 2017, Nature Biotechnology.
[21] E. Segala,et al. Structures of Human A1 and A2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity. , 2017, Structure.
[22] S. Antonia,et al. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment , 2017, Neoplasia.
[23] Nicole Diedrichs,et al. Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases , 2017, ChemMedChem.
[24] Arthur Christopoulos,et al. Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity , 2017, Cell.
[25] A. Leslie,et al. Structure of the adenosine A2A receptor bound to an engineered G protein , 2016, Nature.
[26] A. IJzerman,et al. Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength. , 2016, Journal of medicinal chemistry.
[27] X. García‐Mera,et al. Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes. , 2016, Journal of medicinal chemistry.
[28] A. Christopoulos,et al. A Positive Allosteric Modulator of the Adenosine A1 Receptor Selectively Inhibits Primary Afferent Synaptic Transmission in a Neuropathic Pain Model , 2015, Molecular Pharmacology.
[29] Axel Hoos,et al. Big opportunities for small molecules in immuno-oncology , 2015, Nature Reviews Drug Discovery.
[30] A. Leslie,et al. Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor , 2015, Molecular Pharmacology.
[31] Wentao Zhang,et al. Adenosine A2B receptor stimulates angiogenesis by inducing VEGF and eNOS in human microvascular endothelial cells , 2015, Experimental biology and medicine.
[32] J. Powell,et al. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy , 2015, Computational and structural biotechnology journal.
[33] Woody Sherman,et al. Selecting an Optimal Number of Binding Site Waters To Improve Virtual Screening Enrichments Against the Adenosine A2A Receptor , 2014, J. Chem. Inf. Model..
[34] Manuel de Lera Ruiz,et al. Adenosine A2A receptor as a drug discovery target. , 2014, Journal of medicinal chemistry.
[35] Joanne Baltos,et al. Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist , 2014, Proceedings of the National Academy of Sciences.
[36] B. Cronstein,et al. Rolofylline, an adenosine A1 receptor antagonist, inhibits osteoclast differentiation as an inverse agonist , 2013, British journal of pharmacology.
[37] C. Langmead,et al. Pharmacology and Structure of Isolated Conformations of the Adenosine A2A Receptor Define Ligand Efficacy , 2013, Molecular Pharmacology.
[38] Peter Kolb,et al. Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A1 Adenosine Receptor Antagonists , 2012, PloS one.
[39] Woody Sherman,et al. Current Assessment of Docking into GPCR Crystal Structures and Homology Models: Successes, Challenges, and Guidelines , 2012, J. Chem. Inf. Model..
[40] H. V. van Vlijmen,et al. Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data. , 2012, Journal of medicinal chemistry.
[41] R. Stevens,et al. Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.
[42] A. IJzerman,et al. Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time , 2012, British journal of pharmacology.
[43] Francesca Deflorian,et al. Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. , 2012, Journal of medicinal chemistry.
[44] K. Leineweber,et al. Partial adenosine A1 receptor agonists for cardiovascular therapies , 2012, Purinergic Signalling.
[45] Nathan Robertson,et al. Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .
[46] Jonathan S. Mason,et al. Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design , 2012, Journal of medicinal chemistry.
[47] S. Iwata,et al. G protein-coupled receptor inactivation by an allosteric inverse-agonist antibody , 2011, Nature.
[48] A. Bender,et al. Substructure‐Based Virtual Screening for Adenosine A2A Receptor Ligands , 2011, ChemMedChem.
[49] M. Congreve,et al. Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. , 2011, Structure.
[50] A. Leslie,et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.
[51] Kenneth A Jacobson,et al. Recent developments in adenosine receptor ligands and their potential as novel drugs. , 2011, Biochimica et biophysica acta.
[52] R. Stevens,et al. Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.
[53] B. Fredholm,et al. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update , 2011, Pharmacological Reviews.
[54] B. Fredholm,et al. Peripheral adenosine A2A receptors are involved in carrageenan-induced mechanical hyperalgesia in mice , 2010, Neuroscience.
[55] K. Jacobson,et al. Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. , 2010, Bioorganic & medicinal chemistry letters.
[56] B. Fredholm,et al. Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[57] K. Varani,et al. Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes , 2010, British journal of pharmacology.
[58] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[59] Judy Lin,et al. Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. , 2010, Journal of medicinal chemistry.
[60] A. Ohta,et al. The A2aR adenosine receptor controls cytokine production in iNKT cells , 2010, European journal of immunology.
[61] Sergio Paredes,et al. Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. , 2010, Bioorganic & medicinal chemistry letters.
[62] B. Fredholm,et al. Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. , 2010, Arthritis and rheumatism.
[63] Ruben Abagyan,et al. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.
[64] S. Masino,et al. Control of Cannabinoid CB1 Receptor Function on Glutamate Axon Terminals by Endogenous Adenosine Acting at A1 Receptors , 2010, The Journal of Neuroscience.
[65] K. Klotz,et al. Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A3 receptor. , 2009, Journal of Medicinal Chemistry.
[66] H. Yin,et al. Genetic Deletion of A2A Adenosine Receptors in the Striatum Selectively Impairs Habit Formation , 2009, The Journal of Neuroscience.
[67] Xiu Song,et al. Preferential enhancement of working memory in mice lacking adenosine A2A receptors , 2009, Brain Research.
[68] Farag F. Sherbiny,et al. Homology modelling of the human adenosine A2B receptor based on X-ray structures of bovine rhodopsin, the β2-adrenergic receptor and the human adenosine A2A receptor , 2009, J. Comput. Aided Mol. Des..
[69] B. Fredholm,et al. Absence of adenosine A1 receptors unmasks pulses of insulin release and prolongs those of glucagon and somatostatin. , 2009, Life sciences.
[70] J. Linden,et al. Adenosine A2B receptors are highly expressed on murine type II alveolar epithelial cells. , 2009, American journal of physiology. Lung cellular and molecular physiology.
[71] Arthur Christopoulos,et al. Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. , 2009, Journal of medicinal chemistry.
[72] Thomas Borrmann,et al. 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. , 2009, Journal of medicinal chemistry.
[73] K. Jacobson,et al. Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor. , 2009, Journal of medicinal chemistry.
[74] Dharini van der Hoeven,et al. Characterization of the A2B Adenosine Receptor from Mouse, Rabbit, and Dog , 2009, Journal of Pharmacology and Experimental Therapeutics.
[75] K. Klotz,et al. N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice. , 2009, Journal of medicinal chemistry.
[76] R. Greene,et al. Control and Function of the Homeostatic Sleep Response by Adenosine A1 Receptors , 2009, The Journal of Neuroscience.
[77] Jiang-Fan Chen,et al. Genetic inactivation of adenosine A2A receptors attenuates acute traumatic brain injury in the mouse cortical impact model , 2009, Experimental Neurology.
[78] Thea Mulder-Krieger,et al. A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. , 2009, Journal of medicinal chemistry.
[79] A. Knight,et al. Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. , 2009, Journal of medicinal chemistry.
[80] B. Fredholm,et al. Decreased behavioral activation following caffeine, amphetamine and darkness in A3 adenosine receptor knock-out mice , 2008, Physiology & Behavior.
[81] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[82] B. Fredholm,et al. Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue-interactions with insulin. , 2008, European journal of pharmacology.
[83] J. P. Petzer,et al. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. , 2008, Bioorganic & medicinal chemistry.
[84] B. Fredholm,et al. Adenosine induces airway hyperresponsiveness through activation of A3 receptors on mast cells. , 2008, The Journal of allergy and clinical immunology.
[85] G. Shaked,et al. Anti-Inflammatory Preconditioning by Agonists of Adenosine A1 Receptor , 2008, PloS one.
[86] K. Jacobson,et al. Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. , 2008, Bioorganic & medicinal chemistry letters.
[87] J. Tsien,et al. A Critical Role of the Adenosine A2A Receptor in Extrastriatal Neurons in Modulating Psychomotor Activity as Revealed by Opposite Phenotypes of Striatum and Forebrain A2A Receptor Knock-Outs , 2008, The Journal of Neuroscience.
[88] Ying Sun,et al. Adenosine Promotes IL-6 Release in Airway Epithelia1 , 2008, The Journal of Immunology.
[89] David A. Lustig,et al. Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. , 2008, Journal of medicinal chemistry.
[90] T. Eckle,et al. A2B adenosine receptor dampens hypoxia-induced vascular leak. , 2008, Blood.
[91] J. Downey,et al. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. , 2007, Journal of molecular and cellular cardiology.
[92] B. Hocher,et al. The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure , 2007, British journal of pharmacology.
[93] M. Loza,et al. Discovery and characterization of 4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist. , 2007, Journal of medicinal chemistry.
[94] B. Fredholm,et al. Sex differences in mouse heart rate and body temperature and in their regulation by adenosine A1 receptors , 2007, Acta physiologica.
[95] B. Fredholm,et al. Eliminating the antilipolytic adenosine A1 receptor does not lead to compensatory changes in the antilipolytic actions of PGE2 and nicotinic acid , 2007, Acta physiologica.
[96] C. Ledent,et al. Cardioprotection by Ecto-5′-Nucleotidase (CD73) and A2B Adenosine Receptors , 2007, Circulation.
[97] K. Klotz,et al. [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor. , 2007, European journal of pharmacology.
[98] A. IJzerman,et al. ZM241385, DPCPX, MRS1706 Are Inverse Agonists with Different Relative Intrinsic Efficacies on Constitutively Active Mutants of the Human Adenosine A2B Receptor , 2007, Journal of Pharmacology and Experimental Therapeutics.
[99] A. IJzerman,et al. 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. , 2007, Journal of medicinal chemistry.
[100] Linda Yip,et al. ATP Release Guides Neutrophil Chemotaxis via P2Y2 and A3 Receptors , 2006, Science.
[101] Xiaowei Jin,et al. Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. , 2006, Journal of medicinal chemistry.
[102] K. Klotz,et al. Improving Potency, Selectivity, and Water Solubility of Adenosine A1 Receptor Antagonists: Xanthines Modified at Position 3 and Related Pyrimido[1,2,3‐cd]purinediones , 2006, ChemMedChem.
[103] Pál Pacher,et al. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases , 2006, Nature Reviews Drug Discovery.
[104] C. Müller,et al. Characterization of human and rodent native and recombinant adenosine A2B receptors by radioligand binding studies , 2006, Purinergic Signalling.
[105] M. Koupenova,et al. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. , 2006, The Journal of clinical investigation.
[106] M. Sitkovsky,et al. Adenosine A2a receptors induce heterologous desensitization of chemokine receptors. , 2006, Blood.
[107] J. Falck,et al. Adenosine2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway. , 2006, American journal of physiology. Renal physiology.
[108] Xiaowei Jin,et al. Norbornyllactone-substituted xanthines as adenosine A(1) receptor antagonists. , 2006, Bioorganic & medicinal chemistry.
[109] Johannes Brussee,et al. Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. , 2006, Journal of medicinal chemistry.
[110] B. Fredholm,et al. Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning. , 2006, American journal of physiology. Heart and circulatory physiology.
[111] E. Kidd,et al. Radioligand binding and functional responses of ligands for human recombinant adenosine A(3) receptors. , 2006, Autonomic & autacoid pharmacology.
[112] P. Kochanek,et al. Adenosine A1 Receptor Knockout Mice Develop Lethal Status Epilepticus after Experimental Traumatic Brain Injury , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[113] J. Huidobro-Toro,et al. The role of adenosine A2A and A3 receptors on the differential modulation of norepinephrine and neuropeptide Y release from peripheral sympathetic nerve terminals , 2006, Journal of neurochemistry.
[114] K. Jacobson,et al. Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.
[115] A. IJzerman,et al. Allosteric modulation, thermodynamics and binding to wild‐type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine‐like agonist , 2006, British journal of pharmacology.
[116] R. Cunha,et al. Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat , 2005, Neuroscience.
[117] C. Saper,et al. Deletion of presynaptic adenosine A1 receptors impairs the recovery of synaptic transmission after hypoxia , 2005, Neuroscience.
[118] S. Masino,et al. Adenosine and ATP Link PCO2 to Cortical Excitability via pH , 2005, Neuron.
[119] E. Vizi,et al. Adenosine Augments IL-10 Production by Macrophages through an A2B Receptor-Mediated Posttranscriptional Mechanism1 , 2005, The Journal of Immunology.
[120] K. Klotz,et al. Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. , 2005, Biochemical pharmacology.
[121] M. Morelli,et al. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. , 2005, Life sciences.
[122] A. Nadeem,et al. A Novel A1 Adenosine Receptor Antagonist, L-97-1 [3-[2-(4-Aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], Reduces Allergic Responses to House Dust Mite in an Allergic Rabbit Model of Asthma , 2005, Journal of Pharmacology and Experimental Therapeutics.
[123] A. Kurtz,et al. Blood Pressure–Dependent Inhibition of Renin Secretion Requires A1 Adenosine Receptors , 2005, Hypertension.
[124] Giovanni Piersanti,et al. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. , 2005, Journal of medicinal chemistry.
[125] E. Jackson,et al. Adenosine Inhibits PDGF-Induced Growth of Human Glomerular Mesangial Cells Via A2B Receptors , 2005, Hypertension.
[126] R. Germack,et al. Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. , 2005, Journal of molecular and cellular cardiology.
[127] B. Fredholm,et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine , 2005, Nature Neuroscience.
[128] B. Fredholm,et al. Mice lacking the adenosine A1 receptor have normal spatial learning and plasticity in the CA1 region of the hippocampus, but they habituate more slowly , 2005, Synapse.
[129] G. Matherne,et al. Myocardial function following cold ischemic storage is improved by cardiac-specific overexpression of A1-adenosine receptors. , 2005, Canadian journal of physiology and pharmacology.
[130] P. Jenner. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease , 2005, Expert opinion on investigational drugs.
[131] B. Fredholm,et al. Luminal adenosine stimulates chloride secretion through A1 receptor in mouse jejunum. , 2005, American journal of physiology. Gastrointestinal and liver physiology.
[132] J. Huidobro-Toro,et al. A2B adenosine receptor mediates human chorionic vasoconstriction and signals through arachidonic acid cascade. , 2005, American journal of physiology. Heart and circulatory physiology.
[133] R. Leurs,et al. A "locked-on," constitutively active mutant of the adenosine A1 receptor. , 2005, European journal of pharmacology.
[134] C. Müller,et al. Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats , 2005, Psychopharmacology.
[135] S. Dohi,et al. Effects of adenosine agonist R-phenylisopropyl-adenosine on halothane anesthesia and antinociception in rats , 2005, Acta Pharmacologica Sinica.
[136] B. Fredholm,et al. Increased nociceptive response in mice lacking the adenosine A1 receptor , 2005, Pain.
[137] K. Jacobson,et al. 2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors. , 2004, Biochemical pharmacology.
[138] A. IJzerman,et al. Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist‐specific G protein activation , 2004, British journal of pharmacology.
[139] R. Germack,et al. Activation of protein kinase B by adenosine A1 and A3 receptors in newborn rat cardiomyocytes. , 2004, Journal of molecular and cellular cardiology.
[140] A. Iwashita,et al. Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors. , 2004, Journal of pharmacological sciences.
[141] B. Fredholm,et al. Deletion of the adenosine A1 receptor gene does not alter neuronal damage following ischaemia in vivo or in vitro , 2004, The European journal of neuroscience.
[142] C. Diniz,et al. Facilitation of noradrenaline release by activation of adenosine A(2A) receptors triggers both phospholipase C and adenylate cyclase pathways in rat tail artery. , 2004, Cardiovascular research.
[143] A. Castelhano,et al. [3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors. , 2004, Biochemical pharmacology.
[144] M. Loza,et al. Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor. , 2004, Journal of medicinal chemistry.
[145] A. IJzerman,et al. New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. , 2004, Journal of medicinal chemistry.
[146] S. Muchnik,et al. Presynaptic inhibition of spontaneous acetylcholine release induced by adenosine at the mouse neuromuscular junction , 2004, British journal of pharmacology.
[147] B. Krämer,et al. Gene expression of adenosine receptors along the nephron. , 2004, Kidney international.
[148] M. W. George,et al. Quantitative analysis of the formation and diffusion of A1-adenosine receptor-antagonist complexes in single living cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[149] A. IJzerman,et al. The mouse brain adenosine A1 receptor: functional expression and pharmacology. , 2004, European journal of pharmacology.
[150] B. Fredholm,et al. Involvement of A1 adenosine receptors in the acquisition of fertilizing capacity. , 2004, Journal of andrology.
[151] B. Fredholm,et al. Binding of the prototypical adenosine A2A receptor agonist CGS 21680 to the cerebral cortex of adenosine A1 and A2A receptor knockout mice , 2004, British journal of pharmacology.
[152] K. Varani,et al. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. , 2004, Journal of medicinal chemistry.
[153] G. Hartmann,et al. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. , 2004, Blood.
[154] S. Nasr,et al. A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion. , 2004, American journal of physiology. Renal physiology.
[155] C. Müller,et al. Antinociceptive Effects of Novel A2B Adenosine Receptor Antagonists , 2004, Journal of Pharmacology and Experimental Therapeutics.
[156] S. Schulz,et al. Heterodimerization of Substance P and μ-Opioid Receptors Regulates Receptor Trafficking and Resensitization* , 2003, Journal of Biological Chemistry.
[157] C. Dourish,et al. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson’s disease , 2003, Neurology.
[158] P. Jenner,et al. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD , 2003, Neurology.
[159] T. Sato,et al. Involvement of adenosine A1 receptors in forced walking stress-induced analgesia in mice. , 2003, Methods and Findings in Experimental and Clinical Pharmacology.
[160] B. Fredholm,et al. Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor , 2003, Journal of Sleep Research.
[161] B. Fredholm,et al. Distribution of antinociceptive adenosine a1 receptors in the spinal cord dorsal horn, and relationship to primary afferents and neuronal subpopulations , 2003, Neuroscience.
[162] C. Müller,et al. Adenosine receptor agonists: from basic medicinal chemistry to clinical development , 2003, Expert opinion on emerging drugs.
[163] Jiang-Fan Chen,et al. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment. , 2003, Drug news & perspectives.
[164] H. Lipp,et al. Emotional instability but intact spatial cognition in adenosine receptor 1 knock out mice , 2003, Behavioural Brain Research.
[165] B. Fredholm,et al. A1 adenosine receptors mediate hypoxia-induced ventriculomegaly , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[166] W. Hauber,et al. Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats , 2003, Synapse.
[167] R. Cunha,et al. Adenosine A3 receptors are located in neurons of the rat hippocampus , 2003, Neuroreport.
[168] J. Fozard,et al. Antagonist pharmacology of adenosine A2B receptors from rat, guinea pig and dog. , 2003, European journal of pharmacology.
[169] R. J. Hill,et al. Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. , 2003, American journal of physiology. Heart and circulatory physiology.
[170] C. Ledent,et al. Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor , 2003, Behavioural Brain Research.
[171] J. Dickenson,et al. Functional expression of adenosine A2A and A3 receptors in the mouse dendritic cell line XS-106. , 2003, European journal of pharmacology.
[172] C. Saper,et al. Focal Deletion of the Adenosine A1 Receptor in Adult Mice Using an Adeno-Associated Viral Vector , 2003, The Journal of Neuroscience.
[173] M. Jacobson,et al. References Subscriptions Permissions Email Alerts A Class I MHC-Restricted Recall Response to a Viral Peptide Is Highly Polyclonal Despite Stringent CDR3 Selection: Implications for Establishing Memory T Cell Repertoires in ''Real-World' ' Conditions , 2013 .
[174] M. Tsai,et al. Identification of A3 Receptor- and Mast Cell-Dependent and -Independent Components of Adenosine-Mediated Airway Responsiveness in Mice1 , 2003, The Journal of Immunology.
[175] 山本 秀一郎. Intrathecal adenosine A_1 receptor agonist attenuates hyperalgesia without inhibiting spinal glutamate release in the rat , 2003 .
[176] Kenneth A. Jacobson,et al. Behavioral Characterization of Mice Lacking the A3 Adenosine Receptor: Sensitivity to Hypoxic Neurodegeneration , 2003, Cellular and molecular neurobiology.
[177] A. IJzerman,et al. 2,8-Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor. , 2003, Bioorganic & medicinal chemistry.
[178] V. Libri,et al. Effect of the Adenosine A1 Receptor Agonist Gr79236 on Trigeminal Nociception with Blink Reflex Recordings in Healthy Human Subjects , 2003, Cephalalgia : an international journal of headache.
[179] T. Ishikawa,et al. Intrathecal Adenosine A1 Receptor Agonist Attenuates Hyperalgesia Without Inhibiting Spinal Glutamate Release in the Rat , 2003, Cellular and Molecular Neurobiology.
[180] C. Ledent,et al. Endogenous Adenosine Increases Coronary Flow by Activation of Both A2A and A2B Receptors in Mice , 2003, Journal of cardiovascular pharmacology.
[181] Adriaan P IJzerman,et al. N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. , 2003, Journal of medicinal chemistry.
[182] G. Breithardt,et al. Altered sinus nodal and atrioventricular nodal function in freely moving mice overexpressing the A1 adenosine receptor. , 2003, American journal of physiology. Heart and circulatory physiology.
[183] B. Fredholm,et al. Aggravated Brain Damage After Hypoxic Ischemia in Immature Adenosine A2A Knockout Mice , 2003, Stroke.
[184] G. Marks,et al. Enhancement of rapid eye movement sleep in the rat by actions at A1 and A2a adenosine receptor subtypes with a differential sensitivity to atropine , 2003, Neuroscience.
[185] K. Jacobson,et al. 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. , 2003, Bioorganic & medicinal chemistry.
[186] V. D’Agati,et al. A3 adenosine receptor knockout mice are protected against ischemia- and myoglobinuria-induced renal failure. , 2003, American journal of physiology. Renal physiology.
[187] J. Headrick,et al. Adenosine Receptor Subtypes Mediating Coronary Vasodilation in Rat Hearts , 2003, Journal of cardiovascular pharmacology.
[188] M. Storr,et al. Modulatory effect of adenosine receptors on the ascending and descending neural reflex responses of rat ileum , 2002, BMC Neuroscience.
[189] C. Ledent,et al. Low Ethanol Sensitivity and Increased Ethanol Consumption in Mice Lacking Adenosine A2A Receptors , 2002, The Journal of Neuroscience.
[190] B. Fredholm,et al. Decreased inflammatory pain due to reduced carrageenan-induced inflammation in mice lacking adenosine A3 receptors , 2002, Neuroscience.
[191] Dirk Bier,et al. Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. , 2002, Journal of medicinal chemistry.
[192] M. Mocanu,et al. Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury. , 2002, American journal of physiology. Heart and circulatory physiology.
[193] Richard A Stone,et al. Knockout of A3 adenosine receptors reduces mouse intraocular pressure. , 2002, Investigative ophthalmology & visual science.
[194] Kenneth A Jacobson,et al. Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. , 2002, Journal of medicinal chemistry.
[195] B. Fredholm,et al. Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate , 2002, The European journal of neuroscience.
[196] L. Worrall,et al. Induction of interleukin 8 release from the HMC-1 mast cell line: synergy between stem cell factor and activators of the adenosine A(2b) receptor. , 2002, Biochemical pharmacology.
[197] K. Klotz,et al. N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. , 2002, Journal of medicinal chemistry.
[198] H. Yee,et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. , 2002, The American journal of pathology.
[199] J. Shimada,et al. KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. , 2002, European journal of pharmacology.
[200] K. Jacobson,et al. Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. , 2002, Journal of medicinal chemistry.
[201] R. Kukreja,et al. Late preconditioning elicited by activation of adenosine A(3) receptor in heart: role of NF- kappa B, iNOS and mitochondrial K(ATP) channel. , 2002, Journal of molecular and cellular cardiology.
[202] E. Piña,et al. Regulation of glycogen metabolism in hepatocytes through adenosine receptors. Role of Ca2+ and cAMP. , 2002, European journal of pharmacology.
[203] C. Müller,et al. 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. , 2002, Journal of medicinal chemistry.
[204] A. IJzerman,et al. 2,5'-Disubstituted adenosine derivatives: evaluation of selectivity and efficacy for the adenosine A(1), A(2A), and A(3) receptor. , 2002, Journal of medicinal chemistry.
[205] A. Ohta,et al. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage , 2001, Nature.
[206] B. Fredholm,et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.
[207] T. Scammell,et al. An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons , 2001, Neuroscience.
[208] I. Biaggioni,et al. Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2). , 2001, Biochemical pharmacology.
[209] B. Fredholm,et al. Abolished tubuloglomerular feedback and increased plasma renin in adenosine A1 receptor-deficient mice. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[210] Jianjing Xue,et al. Differential gene expression of adenosine A1, A2a, A2b, and A3 receptors in the human enteric nervous system , 2001, The Journal of comparative neurology.
[211] Q. Dong,et al. Overexpression of the A1 adenosine receptor in adipose tissue protects mice from obesity‐related insulin resistance , 2001, Diabetes, obesity & metabolism.
[212] Z. Yang,et al. Targeted deletion of A(3) adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium. , 2001, American journal of physiology. Heart and circulatory physiology.
[213] Tianxin Yang,et al. Mediation of tubuloglomerular feedback by adenosine: Evidence from mice lacking adenosine 1 receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[214] B. Fredholm,et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[215] T. Skalak,et al. Selective A(2A) adenosine receptor activation reduces skin pressure ulcer formation and inflammation. , 2001, American journal of physiology. Heart and circulatory physiology.
[216] C. Allegrucci,et al. Stimulation by N6-Cyclopentyladenosine of A1 Adenosine Receptors, Coupled to Gαi2 Protein Subunit, Has a Capacitative Effect on Human Spermatozoa1 , 2001, Biology of reproduction.
[217] A. Ngai,et al. Receptor subtypes mediating adenosine-induced dilation of cerebral arterioles. , 2001, American journal of physiology. Heart and circulatory physiology.
[218] J. Mcpherson,et al. Adenosine A2A Receptor Stimulation Reduces Inflammation and Neointimal Growth in a Murine Carotid Ligation Model , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[219] Alexandre de Mendonça,et al. A functional role for adenosine A3 receptors: modulation of synaptic plasticity in the rat hippocampus , 2001, Neuroscience Letters.
[220] W. Bao,et al. Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. , 2001, Journal of molecular and cellular cardiology.
[221] K. Jacobson,et al. [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. , 2001, Biochemical pharmacology.
[222] Mauro Papotti,et al. Immunohistochemical localization of adenosine A1 receptors in human brain regions , 2001, Neuroscience Letters.
[223] A. IJzerman,et al. Why are A(2B) receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A(2B) receptor for 2-(1-Hexynyl)adenosine. , 2000, Molecular pharmacology.
[224] F. Fazio,et al. Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography. , 2000, Journal of medicinal chemistry.
[225] A. Masamune,et al. Activation of adenosine A1-receptor pathway induces edema formation in the pancreas of rats. , 2000, Gastroenterology.
[226] C. Lluis,et al. Immunolocalization of A1 Adenosine Receptors in Mammalian Spermatozoa , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[227] B. Fredholm,et al. Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. , 2000, Molecular pharmacology.
[228] K. Jacobson,et al. Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulation. , 2000, Biochemical pharmacology.
[229] E. Ongini,et al. Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors : functional and biochemical aspects. , 2000, Circulation.
[230] C. Müller,et al. Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes--a new, selective antagonist radioligand for A(2A) adenosine receptors. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[231] A. IJzerman,et al. Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. , 2000, Journal of medicinal chemistry.
[232] K. Klotz,et al. [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. , 2000, Molecular pharmacology.
[233] S. Rivkees,et al. A1 adenosine receptor activation increases adipocyte leptin secretion. , 2000, Endocrinology.
[234] D. Standaert,et al. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A2A adenosine receptors , 2000, Neuroscience.
[235] H. Gavras,et al. A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. , 2000, Biochimica et biophysica acta.
[236] K. Jacobson,et al. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. , 2000, Journal of medicinal chemistry.
[237] Beverly H. Koller,et al. Disruption of the A3 Adenosine Receptor Gene in Mice and Its Effect on Stimulated Inflammatory Cells* , 2000, The Journal of Biological Chemistry.
[238] G. Spalluto,et al. Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors. , 2000, Bioorganic & medicinal chemistry letters.
[239] C. Franceschi,et al. Activation of the A3 adenosine receptor affects cell cycle progression and cell growth , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.
[240] M. Jacobson,et al. Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells. , 2000, The Journal of clinical investigation.
[241] K. Klotz,et al. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. , 2000, Journal of medicinal chemistry.
[242] V. Vallon,et al. Adenosine formed by 5'-nucleotidase mediates tubuloglomerular feedback. , 2000, The Journal of clinical investigation.
[243] P. Svenningsson,et al. Distribution, biochemistry and function of striatal adenosine A2A receptors , 1999, Progress in Neurobiology.
[244] K. Jacobson,et al. Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. , 1999, Drug design and discovery.
[245] M. Moskowitz,et al. A2A Adenosine Receptor Deficiency Attenuates Brain Injury Induced by Transient Focal Ischemia in Mice , 1999, The Journal of Neuroscience.
[246] J. Xaus,et al. Adenosine inhibits macrophage colony-stimulating factor-dependent proliferation of macrophages through the induction of p27kip-1 expression. , 1999, Journal of immunology.
[247] J. Linden,et al. Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. , 1999, Molecular pharmacology.
[248] A. IJzerman,et al. Allosteric modulation of the adenosine A(1) receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. , 1999, Journal of medicinal chemistry.
[249] E. Ongini,et al. Caffeine alters A2A adenosine receptors and their function in human platelets. , 1999, Circulation.
[250] T. Maeda,et al. Region‐dependent difference in the sleep‐promoting potency of an adenosine A2A receptor agonist , 1999, The European journal of neuroscience.
[251] C. Ezeamuzie,et al. Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release , 1999, British journal of pharmacology.
[252] K. Jacobson,et al. 1,3‐dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors , 1999, Drug development research.
[253] K. Ravid,et al. Characterization of the mouse A3 adenosine receptor gene: exon/intron organization and promoter activity. , 1999, Genomics.
[254] T. Cocks,et al. Adenosine mediates relaxation of human small resistance‐like coronary arteries via A2B receptors , 1999, British journal of pharmacology.
[255] F. Pedata,et al. Striatal A2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats. , 1999, Neuroreport.
[256] M. Mirabet,et al. Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation. , 1999, Journal of cell science.
[257] S. Rivkees,et al. Identification of the Adenine Binding Site of the Human A1 Adenosine Receptor* , 1999, The Journal of Biological Chemistry.
[258] P. Schofield,et al. Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors. , 1998, Biochemical pharmacology.
[259] J. Linden,et al. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system , 1998, The Journal of comparative neurology.
[260] L. Berrino,et al. The role of A3 adenosine receptors in central regulation of arterial blood pressure , 1998, British journal of pharmacology.
[261] A. IJzerman,et al. A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds. , 1998, Journal of medicinal chemistry.
[262] A. IJzerman,et al. A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. , 1998, Journal of medicinal chemistry.
[263] G. Spalluto,et al. A2A-adenosine receptor reserve for coronary vasodilation. , 1998, Circulation.
[264] S. Moro,et al. Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. , 1998, Journal of medicinal chemistry.
[265] O. Hayaishi,et al. Involvement of adenosine A2A receptor in sleep promotion. , 1998, European journal of pharmacology.
[266] J. Marshall,et al. Role of adenosine and its receptors in the vasodilatation induced in the cerebral cortex of the rat by systemic hypoxia , 1998, The Journal of physiology.
[267] C. Martini,et al. 2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. , 1998, Journal of medicinal chemistry.
[268] J. Sawynok,et al. Antinociception by adenosine analogs and inhibitors of adenosine metabolism in an inflammatory thermal hyperalgesia model in the rat , 1998, Pain.
[269] B. Fredholm,et al. Comparative pharmacology of human adenosine receptor subtypes – characterization of stably transfected receptors in CHO cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[270] J. Linden,et al. Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. , 1997, Molecular pharmacology.
[271] R. Leurs,et al. Heterologous expression of rat epitope‐tagged histamine H2 receptors in insect Sf9 cells , 1997, British journal of pharmacology.
[272] Hiroshi Kase,et al. Adenosine A2A antagonists with potent anti-cataleptic activity , 1997 .
[273] A. Sollevi,et al. Intrathecal Adenosine Analog Administration Reduces Substance P in Cerebrospinal Fluid Along with Behavioral Effects That Suggest Antinociception in Rats , 1997, Anesthesia and analgesia.
[274] K. Jacobson,et al. Pharmacological characterization of novel A3 adenosine receptor-selective antagonists , 1997, Neuropharmacology.
[275] P. Schofield,et al. Cloning, characterisation and chromosomal assignment of the human adenosine A3 receptor (ADORA3) gene 1 GenBank™ accession numbers: L77729 and L77730. 1 , 1997, Neuroscience Research.
[276] S. Schiffmann,et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor , 1997, Nature.
[277] J. Linden,et al. Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[278] R. Lum,et al. Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine. , 1997, Journal of medicinal chemistry.
[279] B. Fredholm,et al. Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]‐SCH 58261 , 1997, British journal of pharmacology.
[280] G Burnstock,et al. Towards a revised nomenclature for P1 and P2 receptors. , 1997, Trends in pharmacological sciences.
[281] M. Olah. Identification of A2a Adenosine Receptor Domains Involved in Selective Coupling to GS , 1997, The Journal of Biological Chemistry.
[282] U. Schwabe,et al. Characterization of a novel adenosine binding protein sensitive to cyclic AMP in rat brain cytosolic and particulate fractions. , 1996, Biochemical pharmacology.
[283] K. Jacobson,et al. 6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. , 1996, Journal of medicinal chemistry.
[284] Stephen P. H. Alexander,et al. Characterization of the human brain putative A2B adenosine receptor expressed in Chinese hamster ovary (CHO.A2B4) cells , 1996, British journal of pharmacology.
[285] K. Jacobson,et al. Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. , 1996, Journal of medicinal chemistry.
[286] E. Ongini,et al. The selective adenosine A2A receptor antagonist SCH 58261 discriminates between two different binding sites for [3H]-CGS 21680 in the rat brain , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.
[287] B. Stein,et al. Adenosine Receptor Antagonists: Structures and Potential Therapeutic Applications , 1996, Current Pharmaceutical Design.
[288] B. Fredholm,et al. Pharmacology of adenosine A2A receptors. , 1996, Trends in pharmacological sciences.
[289] E. Ongini,et al. Labeling of A2A adenosine receptors in human platelets by use of the new nonxanthine antagonist radioligand [3H]SCH 58261. , 1996, The Journal of pharmacology and experimental therapeutics.
[290] K. Jacobson,et al. Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors. , 1996, Journal of medicinal chemistry.
[291] P. Schofield,et al. Characterization and chromosomal localization of the human A2a adenosine receptor gene: ADORA2A. , 1996, Biochemical and biophysical research communications.
[292] O. Hayaishi,et al. Promotion of sleep mediated by the A2a-adenosine receptor and possible involvement of this receptor in the sleep induced by prostaglandin D2 in rats. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[293] K. Jacobson,et al. Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. , 1996, Journal of medicinal chemistry.
[294] G. Firestein,et al. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. , 1996, Journal of immunology.
[295] M. Edbrooke,et al. Cloning and characterisation of the human adenosine A3 receptor gene , 1996, FEBS letters.
[296] K. Varani,et al. Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]‐CGS 21680 binding , 1996, British journal of pharmacology.
[297] Y. Chern,et al. Characterization of the rat A2a adenosine receptor gene. , 1996, DNA and cell biology.
[298] J. Fozard,et al. Mast cell degranulation following adenosine A3 receptor activation in rats. , 1996, European journal of pharmacology.
[299] C. Darimont,et al. Changes in adenosine A1- and A2-receptor expression during adipose cell differentiation , 1996, Molecular and Cellular Endocrinology.
[300] G. Spalluto,et al. Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors. , 1996, Journal of medicinal chemistry.
[301] B. Fredholm,et al. Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.
[302] R. Wysocki,et al. Characterization of 8-(N-methylisopropyl)amino-N6-(5'-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors. , 1996, The Journal of pharmacology and experimental therapeutics.
[303] J. Gusella,et al. Characterization and Expression of the Human A2a Adenosine Receptor Gene , 1996, Journal of neurochemistry.
[304] P. Popoli,et al. Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. , 1995, European journal of pharmacology.
[305] K. Jacobson,et al. 125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor. , 1995, Molecular pharmacology.
[306] M. Hohenegger,et al. Species differences in A1 adenosine receptor/G protein coupling: identification of a membrane protein that stabilizes the association of the receptor/G protein complex. , 1995, Molecular pharmacology.
[307] I. Biaggioni,et al. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. , 1995, The Journal of clinical investigation.
[308] M. Danhof,et al. Deoxyribose analogues of N6‐cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo , 1995, British journal of pharmacology.
[309] E. Jackson,et al. Selective A1 adenosine receptor antagonism augments beta-adrenergic-induced renin release in vivo. , 1995, The American journal of physiology.
[310] Y. Okada,et al. Adenosine facilitates in vivo neurotransmission in the superior colliculus of the rat. , 1995, Journal of neurophysiology.
[311] E. Wong,et al. Enhancement of adenosine A1 receptor functions by benzoylthiophenes in guinea pig tissues in vitro , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.
[312] T. Palmer,et al. Adenosine receptors , 1995, Neuropharmacology.
[313] T. Palmer,et al. Differential Interaction with and Regulation of Multiple G-proteins by the Rat A3 Adenosine Receptor (*) , 1995, The Journal of Biological Chemistry.
[314] K. Jacobson,et al. A3-adenosine receptors: design of selective ligands and therapeutic prospects. , 1995, Drugs of the future.
[315] Stephen P. H. Alexander,et al. Adenosine receptor-induced cyclic AMP generation and inhibition of 5-hydroxytryptamine release in human platelets. , 1995, British journal of clinical pharmacology.
[316] J. Wess,et al. Site-directed Mutagenesis Identifies Residues Involved in Ligand Recognition in the Human A2a Adenosine Receptor (*) , 1995, The Journal of Biological Chemistry.
[317] M. Jacobson,et al. Cloning and chromosomal localization of the human A2b adenosine receptor gene (ADORA2B) and its pseudogene. , 1995, Genomics.
[318] K. Jacobson,et al. "Cleavable trifunctional" approach to receptor affinity labeling: chemical regeneration of binding to A1-adenosine receptors. , 1995, Bioconjugate chemistry.
[319] E. Ongini,et al. Modeling hemodynamic profiles by telemetry in the rat. A study with A1 and A2a adenosine agonists. , 1995, Hypertension.
[320] B. Fredholm,et al. Further characterization of the binding of the adenosine receptor agonist [3H]CGS 21680 to rat brain using autoradiography , 1995, Neuropharmacology.
[321] J. Linden,et al. The allosteric enhancer, PD 81,723, stabilizes human A1 adenosine receptor coupling to G proteins. , 1995, Biochimica et biophysica acta.
[322] B B Fredholm,et al. Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. , 1995, Pharmacology & toxicology.
[323] A. Strosberg,et al. Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor. , 1994, The Journal of biological chemistry.
[324] S. Rivkees. Localization and characterization of adenosine receptor expression in rat testis. , 1994, Endocrinology.
[325] P. Strong,et al. Characterization of the adenosine receptors mediating hypothermia in the conscious mouse , 1994, British journal of pharmacology.
[326] K. Jacobson,et al. 2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors. , 1994, Journal of medicinal chemistry.
[327] K. Jacobson,et al. Role of the second extracellular loop of adenosine receptors in agonist and antagonist binding. Analysis of chimeric A1/A3 adenosine receptors. , 1994, The Journal of biological chemistry.
[328] K. Jacobson,et al. A binding site model and structure-activity relationships for the rat A3 adenosine receptor. , 1994, Molecular pharmacology.
[329] G Burnstock,et al. Nomenclature and Classification of Purinoceptors* , 2005 .
[330] C. Müller,et al. Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists. , 1994, Journal of medicinal chemistry.
[331] D. Marquardt,et al. Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. , 1994, Journal of immunology.
[332] Stephen P. H. Alexander,et al. Coupling of a transfected human brain A1 adenosine receptor in CHO‐K1 cells to calcium mobilisation via a pertussis toxin‐sensitive mechanism , 1994, British journal of pharmacology.
[333] J. Daly,et al. Functional characterization of the A2b adenosine receptor in NIH 3T3 fibroblasts. , 1994, Biochemical pharmacology.
[334] P. Schofield,et al. A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding. , 1994, The Journal of biological chemistry.
[335] G. Stiles,et al. Characterization of the human A1 adenosine receptor gene. Evidence for alternative splicing. , 1994, The Journal of biological chemistry.
[336] J. Linden,et al. Molecular cloning and characterization of the human A3 adenosine receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[337] C. Müller,et al. Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. , 1993, Journal of medicinal chemistry.
[338] B. Fredholm,et al. The binding of the adenosine A2 receptor selective agonist [3H]CGS 21680 to rat cortex differs from its binding to rat striatum. , 1993, European journal of pharmacology.
[339] G. Firestein,et al. cDNA cloning and sequence analysis of the human A3 adenosine receptor. , 1993, Biochimica et biophysica acta.
[340] T. Stone,et al. Mediation of the neuroprotective action of R‐phenylisopropyladenosine through a centrally located adenosine A1 receptor , 1993, British journal of pharmacology.
[341] K. Jacobson,et al. Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. , 1993, Journal of medicinal chemistry.
[342] R. Vestal,et al. Cardiac functional responses to adenosine by PD 81,723, an allosteric enhancer of the adenosine A1 receptor. , 1993, The American journal of physiology.
[343] S. Heckers,et al. Adenosine A1 receptors in human hippocampus: inhibition of [3H]8-cyclopentyl-1,3-dipropylxanthine binding by antagonist drugs , 1993, Neuroscience Letters.
[344] A. Townsend-Nicholson,et al. Molecular cloning and characterisation of a human brain A1 adenosine receptor cDNA. , 1992, Brain research. Molecular brain research.
[345] S. Hurt,et al. [3H]2-phenylaminoadenosine ([3H]CV 1808) labels a novel adenosine receptor in rat brain. , 1992, The Journal of pharmacology and experimental therapeutics.
[346] J. Dumont,et al. Cloning and functional characterization of a human A1 adenosine receptor. , 1992, Biochemical and biophysical research communications.
[347] T J Furlong,et al. Molecular characterization of a human brain adenosine A2 receptor. , 1992, Brain research. Molecular brain research.
[348] J. Shine,et al. Molecular cloning and expression of an adenosine A2b receptor from human brain. , 1992, Biochemical and biophysical research communications.
[349] G. Stiles,et al. Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[350] Richard J. Miller,et al. Inhibition of quantal transmitter release in the absence of calcium influx by a G protein-linked adenosine receptor at hippocampal synapses , 1992, Neuron.
[351] S. Rivkees,et al. Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. , 1992, Molecular endocrinology.
[352] B. Fredholm,et al. Glucocorticoid receptor activation leads to up-regulation of adenosine A1 receptors and down-regulation of adenosine A2 responses in DDT1 MF-2 smooth muscle cells. , 1991, Molecular pharmacology.
[353] C. Gerfen,et al. Cloning and expression of an A1 adenosine receptor from rat brain. , 1991, Molecular pharmacology.
[354] C. Müller,et al. Caffeine analogs: structure-activity relationships at adenosine receptors. , 1991, Pharmacology.
[355] K. Klotz,et al. Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling , 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.
[356] J. Fergus,et al. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.
[357] G. Sutherland,et al. Binding of the Adenosine A2 Receptor Ligand [3H]CGS 21680 to Human and Rat Brain: Evidence for Multiple Affinity Sites , 1990, Journal of neurochemistry.
[358] P. Hartvig,et al. Effects of Intrathecal Injection of the Adenosine Receptor Agonists R‐Phenylisopropyl‐Adenosine and N‐Ethylcarboxamide‐Adenosine on Nociception and Motor Function in the Rat , 1990, Anesthesia and analgesia.
[359] J. Schnermann,et al. Inhibition of tubuloglomerular feedback during adenosine1 receptor blockade. , 1990, The American journal of physiology.
[360] M. Williams,et al. [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. , 1989, The Journal of pharmacology and experimental therapeutics.
[361] C. O'shaughnessy,et al. A1 adenosine receptor-mediated block of epileptiform activity induced in zero magnesium in rat neocortex in vitro , 1988, Epilepsy Research.
[362] A. Dolphin,et al. Pertussis toxin reverses adenosine inhibition of neuronal glutamate release , 1985, Nature.
[363] R. D. Murray,et al. Effects of adenosine receptor agonists in the isolated, perfused rat kidney. , 1984, The American journal of physiology.
[364] R F Bruns,et al. Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. , 1980, Canadian journal of physiology and pharmacology.
[365] L. Dušek,et al. Erythropoiesis- and thrombopoiesis-characterizing parameters in adenosine A3 receptor knock-out mice. , 2013, Physiological research.
[366] E. Elzein,et al. A1 adenosine receptor agonists and their potential therapeutic applications. , 2008, Expert opinion on investigational drugs.
[367] C. Müller,et al. Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders. , 2007, Recent patents on CNS drug discovery.
[368] Courtney M. Lappas,et al. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. , 2005, Journal of immunology.
[369] B. Fredholm,et al. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. , 2005, Annual review of pharmacology and toxicology.
[370] N. Maulik,et al. Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. , 2005, American journal of physiology. Heart and circulatory physiology.
[371] B. Fredholm,et al. Adenosine A3 receptor-mediated regulation of p38 and extracellular-regulated kinase ERK1/2 via phosphatidylinositol-3'-kinase. , 2004, Biochemical pharmacology.
[372] I. Biaggioni,et al. A(2B) adenosine receptors increase cytokine release by bronchial smooth muscle cells. , 2004, American journal of respiratory cell and molecular biology.
[373] M. Ochi,et al. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. , 2003, Neurology.
[374] K. Ravid,et al. Overexpression of A3 adenosine receptors in smooth, cardiac, and skeletal muscle is lethal to embryos. , 2002, Microvascular research.
[375] C. Müller,et al. [(3)H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([(3)H]PSB-11), a novel high-affinity antagonist radioligand for human A(3) adenosine receptors. , 2002, Bioorganic & medicinal chemistry letters.
[376] M. Parmentier,et al. Absence of the adenosine A(2A) receptor or its chronic blockade decrease ethanol withdrawal-induced seizures in mice. , 2001, Neuropharmacology.
[377] J. Linden,et al. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. , 2001, British journal of pharmacology.
[378] Stephen P. H. Alexander,et al. [(3)H]ZM241385--an antagonist radioligand for adenosine A(2A) receptors in rat brain. , 2001, European Journal of Pharmacology.
[379] E. Ongini,et al. Dose and Time Effects of Caffeine Intake on Human Platelet Adenosine A 2 A Receptors Functional and Biochemical Aspects , 2000 .
[380] P. Svenningsson,et al. Adenosine A(2A) receptors are colocalized with and activate g(olf) in rat striatum. , 2000, Molecular pharmacology.
[381] C. Müller. A2A adenosine receptor antagonists - future drugs for Parkinson's disease? , 2000 .
[382] B. Fredholm,et al. Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. , 1999, Biochemical pharmacology.
[383] B. Fredholm,et al. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[384] B. Fredholm,et al. Signaling via A2A adenosine receptor in four PC12 cell clones , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[385] A. IJzerman,et al. 5'-substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor. , 1998, Journal of medicinal chemistry.
[386] D. J. Triggle,et al. Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for a 3 receptors , 1998 .
[387] G. Stiles,et al. Adenosine receptor subtypes: characterization and therapeutic regulation. , 1995, Annual review of pharmacology and toxicology.
[388] K. Jacobson,et al. Adenosine Receptors:Selective Agonists and Antagonists , 1995 .
[389] J. Daly,et al. Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. , 1993, Pharmacology.
[390] J. Koopman,et al. Differences in the intestinal microflora of normal and dystrophic BIO 8262 Nij Syrian hamsters. , 1990, Zeitschrift fur Versuchstierkunde.